New hope for advanced breast cancer: experimental drug BL-B01D1 takes on chemo
NCT ID NCT06343948
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests a new drug called BL-B01D1 against standard chemotherapy in about 383 people with advanced HR+HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth or improve survival. Participants are randomly assigned to receive either the new drug or a doctor-chosen chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could two years of hormone therapy be enough for some breast cancers?
- Could a targeted drug re-sensitize resistant breast cancer?
- AI reads MRI scans to predict who will benefit from chemo
- Three-Drug cocktail aims to shrink breast tumors before surgery
- Radioactive 'Smart Bombs' target Hard-to-Treat cancers